Entries by Katja Buhrer

Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program

September 10, 2019 in , , /by

San Francisco, (September 10, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company developing novel drugs and biologics, today announced that it has been selected by the National Cancer Institute (NCI) as one of three contractors in response to the solicitation for the PREVENT Cancer Preclinical Drug Development Program (PREVENT): Current Good Manufacturing […]

Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Lake Street Best Ideas Growth Conference, and Cantor Global Healthcare Conference

August 28, 2019 in , , /by

San Francisco, California (August 28, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 10, the Lake Street Best Ideas Growth Conference on September 12, and the Cantor Global Healthcare Conference on October 2, in […]

Kindred Biosciences Announces Second Quarter 2019 Financial Results and Unveils Positive Results from Pilot Efficacy Study of Parvovirus Monoclonal Antibody

August 1, 2019 in , , /by

Mortality benefit seen in both prophylaxis and treatment of parvovirus infection San Francisco, California (August 1, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2019 and provided updates on its programs, including positive results […]

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs

July 29, 2019 in , , /by

– Achieved rapid and dramatic reduction in pruritus (itch) and CADESI score versus placebo.– Call to discuss study results at 8:30 a.m. Eastern time today. San Francisco, California (July 29, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results […]